

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Alvimopan-d₅

Item No. 33812

Formal Name: N-[2-[[(3R,4R)-4-(3-hydroxyphenyl)-

3,4-dimethyl-1-piperidinyl]methyl]-1-

oxo-3-(phenyl-d₅)propyl]-glycine

ADL 8-2698-d₅ Synonym: MF: $C_{25}H_{27}D_5N_2O_4$

FW: 429.6


Chemical Purity: ≥95% (Alvimopan)

Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₅); ≤1% d₀

Supplied as: A solid Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Alvimopan-d₅ is intended for use as an internal standard for the quantification of alvimopan (Item No. 23902) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Alvimopan- d_5 is supplied as a solid. A stock solution may be made by dissolving the alvimopan- d_5 in the solvent of choice, which should be purged with an inert gas. Alvimopan-d₅ is soluble in methanol and DMSO.

Description

Alvimopan is a μ-opioid receptor antagonist ($K_i = 0.47$ nM).¹ It is selective over the κ- and δ-opioid receptors (K_is= 100 nM and 12 nM, respectively). Alvimopan inhibits μ-opioid receptor-mediated GTP binding to CHO cell membranes with an IC_{50} value of 1.7 nM. It inhibits morphine-induced slowing of colorectal transit in mice with an ED₅₀ value of 0.41 mg/kg.² Alvimopan (0.3 and 1 mg/kg, p.o.) reduces inhibition of gastrointestinal (GI) transit induced by morphine, but not apraclonidine (Item No. 23904), in rats. Formulations containing alvimopan have been used in the treatment of opioid-induced bowel dysfunction.

References

- 1. Le Bourdonnec, B., Barker, W.M., Belanger, S., et al. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg. Med. Chem. Lett. 18(6), 2006-2012 (2008).
- 2. Greenwood-Van Meerveld, B., Gardner, C.J., Little, P.J., et al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol. Motil. 16(Suppl. 2), 46-53 (2004).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 04/07/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM